logo-loader
viewTHC Global Group Ltd

THC Global appoints COO at cannabis extraction and manufacturing division

The new COO has more than 30 years’ experience in the pharmaceutical industry in Australia and the UK including roles at PCI Clinical Services, LEO Pharma, IDT Australia, GlaxoSmithKline and Pfizer.

THC Global Group Ltd - THC Global appoints Angela Macquire as chief operating officer at the Southport Facility in QLD
The chief operating officer will begin work at THC Pharma's Southport Facility in late January

THC Global Group Ltd (ASX:THC) has appointed Angela Macquire as chief operating officer of THC Pharma Pty Ltd, the company’s extraction and manufacturing division which operates the Southport Facility in Queensland.

Macquire has more than 30 years’ experience in the pharmaceutical industry including managerial and directorial roles at PCI Clinical Services, LEO Pharma and IDT Australia as well as technical roles at GlaxoSmithKline and Pfizer.

Her experience includes managing the development and commercial manufacture of various pharmaceutical formulations, both sterile and non-sterile and including nasal sprays, ointments, capsules, and tablets for Australian and North American clients to cGMP standards.

Relevant experience

Throughout her career, she has gained significant experience in early phase clinical trials and has recently been involved in managing medicinal cannabis formulations projects for global clients.

This work has included formulation, manufacture and packaging of stable products for use in early phase clinical trials and Special Access Scheme use within the sector.

Scaling-up commercial production

THC Global chief executive officer Ken Charteris said: We’re very excited to bring Angela to THC Pharma, who will lead our team as we scale-up our commercial production of Australian medicinal cannabis for Australian patients and the global export market.

“Angela brings with her significant senior managerial expertise in operating large-scale pharmaceutical operations, as well as technical expertise in pharmaceutical product development, formulation, and clinical trials”.

Set to begin late January 2020

Macquire also has extensive experience working with global pharmaceutical regulators including the Australian Therapeutic Goods Administration and the United States of America’s Food and Drug Administration as well as various Asian and European Regulatory Bodies. A

She will bring to the company’s senior leadership team experience in ensuring compliance with global manufacturing practices and other global medicinal products standards and expectations.

Macquire will begin working from the Southport Facility in late January 2020, supporting the company’s scale-up towards commercial production of Australian medicinal cannabis medicines at this location, which is the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere.

Quick facts: THC Global Group Ltd

Price: 0.255 AUD

ASX:THC
Market: ASX
Market Cap: $35.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of THC Global Group Ltd named herein, including the promotion by the Company of THC Global Group Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

on 29/1/20

2 min read